Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13012174 | 0.84 | PTGES2 (0.55) | PTGES2L3MBTL1NFE2L2KCNH2NPC1 | |
| SCHEMBL13012150 | 0.81 | PTGES2 (0.53) | PTGES2CA12CA9CA1CA2 | |
| SCHEMBL3778421 | 0.78 | NFE2L2 (0.57) | PTGES2NFE2L2KCNH2NPC1RAB9A | |
| SCHEMBL3778415 | 0.78 | NFE2L2 (0.57) | PTGES2NFE2L2KCNH2NPC1RAB9A | |
| SCHEMBL13012177 | 0.77 | PTGES2 (0.55) | PTGES2NFE2L2KCNH2ALDH1A1GAA | |
| SCHEMBL29538287 | 0.77 | ALDH1A1 (0.55) | PTGES2CA12CA9CA1CA2 | |
| SCHEMBL908602 | 0.77 | ALDH1A1 (0.55) | PTGES2CA12CA9CA1CA2 | |
| SCHEMBL13012176 | 0.74 | PTGES2 (0.55) | PTGES2L3MBTL1NFE2L2KCNH2NPC1 | |
| SCHEMBL18441111 | 0.74 | L3MBTL1 (0.46) | PTGES2CA12CA9CA1CA2 | |
| SCHEMBL14686367 | 0.73 | L3MBTL1 (0.46) | PTGES2CA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | PTGES2 30/4885CA12 4390/4885CA9 3411/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | PTGES2 25/4885CA12 4459/4885CA9 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.